The Oxford Vaccine Group's director, Andrew Pollard, said there were "lots of cases" of infections in its Phase III trial in Britain, Brazil and South Africa.
Pfizer Inc. announced on Wednesday that it completed the late-stage trial of its COVID-19 and final results showed 95% efficacy.
The trials were created to measure whether the vaccines stop people from getting sick rather than whether they prevent transmission, which remains to be tested.
"We are going to have a vaccine that can stop COVID-19", Moderna President Stephen Hoge said in a telephone interview.
Pfizer and its German partner, BioNTech, will apply for emergency approval by the U.S. Food and Drug Administration for their COVID-19 vaccine Friday. There are now rather more data accrued with, it is said, no serious side effects.
The UK has also secured doses of Pfizer/BioNTech's COVID-19 vaccine, as well as potential vaccines from Valneva, Sanofi/GlaxoSmithKline, Moderna, Novavax and Johnson & Johnson.
DuPage County reports 887 COVID-19 cases Sunday, 12 deaths
Each of the sites will offer self-administered COVID-19 rapid tests, provided to the municipalities by Monroe County and NY state. No. 5 United Kingdom 215 deaths, behind the record 1,166 April 21, as well 12,155 cases after a record 33,470 on November 12.
The vaccine, developed by the University of Oxford and AstraZeneca, produced fewer side effects in people aged 56 and over than in younger people - a significant finding given that Covid-19 disproportionately causes severe illness among seniors.
"It is likely that vaccines that prevent symptomatic disease will reduce the duration and level of infectiousness, and thus reduce transmission, but we don't yet know if this effect will be large enough to make any meaningful difference to the spread of the virus within communities", said Eleanor Riley, professor of immunology and infectious disease at the University of Edinburgh.
Work began on the vaccine in January and it was developed in under three months, starting human trials - the first in Europe - in April in Oxford. The only severe adverse events experienced by volunteers were fatigue (3.8%) and headaches (2%) after the second dose. "That's a lot more weight and a lot harder for China to ignore", he said during a July event at the Hudson Institute, a Washington-based think tank.At the same event, he also named climate change as "a number one priority" in foreign relations under Biden.
The statement comes shortly after United States pharmaceutical company Moderna announced that it would charge countries that want to buy its candidate vaccine against COVID-19 between $25 and $37 per dose.
"We can be fairly confident now that the RNA (vaccine approach) is looking good.That's also good for the Imperial College vaccine, which is an RNA vaccine".
Its COVID-19 vaccine is mRNA-based - this novel technology uses lipid nanoparticles to carry information which helps the body produce its own active substances to target a range of diseases. The vaccine, which is based on a human adenoviral vector platform, was developed by the Gamaleya Research Institute of Epidemiology and Microbiology and is now completing phase 3 clinical trials.